These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22700885)

  • 1. FGF-23 levels in patients with AKI and risk of adverse outcomes.
    Leaf DE; Wolf M; Waikar SS; Chase H; Christov M; Cremers S; Stern L
    Clin J Am Soc Nephrol; 2012 Aug; 7(8):1217-23. PubMed ID: 22700885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes.
    Leaf DE; Waikar SS; Wolf M; Cremers S; Bhan I; Stern L
    Clin Endocrinol (Oxf); 2013 Oct; 79(4):491-8. PubMed ID: 23414198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery.
    Leaf DE; Christov M; Jüppner H; Siew E; Ikizler TA; Bian A; Chen G; Sabbisetti VS; Bonventre JV; Cai X; Wolf M; Waikar SS
    Kidney Int; 2016 Apr; 89(4):939-48. PubMed ID: 26924052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients.
    Leaf DE; Siew ED; Eisenga MF; Singh K; Mc Causland FR; Srivastava A; Alp Ikizler T; Ware LB; Ginde AA; Kellum JA; Palevsky PM; Wolf M; Waikar SS
    Clin J Am Soc Nephrol; 2018 Apr; 13(4):531-541. PubMed ID: 29519954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of mortality and need for renal replacement therapy in patients of acute kidney injury using fibroblast growth factor 23.
    Fayed A; Radwan WA; Amin M; Gamal A
    Saudi J Kidney Dis Transpl; 2019; 30(5):1044-1051. PubMed ID: 31696842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.
    Nakano C; Hamano T; Fujii N; Matsui I; Tomida K; Mikami S; Inoue K; Obi Y; Okada N; Tsubakihara Y; Isaka Y; Rakugi H
    Clin J Am Soc Nephrol; 2012 May; 7(5):810-9. PubMed ID: 22362065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
    Portale AA; Wolf MS; Messinger S; Perwad F; Jüppner H; Warady BA; Furth SL; Salusky IB
    Clin J Am Soc Nephrol; 2016 Nov; 11(11):1989-1998. PubMed ID: 27561289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor-23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals.
    Brown JR; Katz R; Ix JH; de Boer IH; Siscovick DS; Grams ME; Shlipak M; Sarnak MJ
    Clin J Am Soc Nephrol; 2014 Feb; 9(2):239-46. PubMed ID: 24262510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.
    Ärnlöv J; Carlsson AC; Sundström J; Ingelsson E; Larsson A; Lind L; Larsson TE
    Clin J Am Soc Nephrol; 2013 May; 8(5):781-6. PubMed ID: 23335040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism.
    Bushinsky DA; Spiegel DM; Yuan J; Warren S; Fogli J; Pergola PE
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):103-110. PubMed ID: 30381412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness.
    Leaf DE; Jacob KA; Srivastava A; Chen ME; Christov M; Jüppner H; Sabbisetti VS; Martin A; Wolf M; Waikar SS
    J Am Soc Nephrol; 2017 Jun; 28(6):1877-1885. PubMed ID: 28028134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial differences in markers of mineral metabolism in advanced chronic kidney disease.
    Jovanovich A; Chonchol M; Cheung AK; Kaufman JS; Greene T; Roberts WL; Smits G; Kendrick J;
    Clin J Am Soc Nephrol; 2012 Apr; 7(4):640-7. PubMed ID: 22383748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.
    de Jong MA; Petrykiv SI; Laverman GD; van Herwaarden AE; de Zeeuw D; Bakker SJL; Heerspink HJL; de Borst MH
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):66-73. PubMed ID: 30559106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma FGF23 levels increase rapidly after acute kidney injury.
    Christov M; Waikar SS; Pereira RC; Havasi A; Leaf DE; Goltzman D; Pajevic PD; Wolf M; Jüppner H
    Kidney Int; 2013 Oct; 84(4):776-85. PubMed ID: 23657144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of serum FGF-23 for risk assessment of contrast-associated acute kidney injury and clinical outcomes in patients undergoing coronary angiography.
    Huang SS; Huang PH; Leu HB; Wu TC; Chen JW; Lin SJ
    PLoS One; 2021; 16(7):e0254835. PubMed ID: 34297744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones.
    Taylor EN; Hoofnagle AN; Curhan GC
    Clin J Am Soc Nephrol; 2015 Apr; 10(4):667-75. PubMed ID: 25623233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between mineral and bone disorder in patients with acute kidney injury following cardiac surgery and adverse outcomes.
    Yang T; Wang W; Tang X; Shi P; Zhang L; Yu W; Xie Y; Guo D; Ding F
    BMC Nephrol; 2019 Oct; 20(1):369. PubMed ID: 31615432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23.
    Burnett-Bowie SA; Leder BZ; Henao MP; Baldwin CM; Hayden DL; Finkelstein JS
    Clin J Am Soc Nephrol; 2012 Apr; 7(4):624-31. PubMed ID: 22300739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients.
    Doi Y; Hamano T; Ichimaru N; Tomida K; Obi Y; Fujii N; Yamaguchi S; Oka T; Sakaguchi Y; Matsui I; Kaimori JY; Abe T; Imamura R; Takahara S; Tsubakihara Y; Nonomura N; Isaka Y
    Sci Rep; 2020 Aug; 10(1):13766. PubMed ID: 32792668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.